Delving into the Latest Updates on ATAP-M8 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Beijing Aitaipu Biomedical Technology Co., Ltd

Active Organization

Beijing Aitaipu Biomedical Technology Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价注射用ATAP-M8在晚期实体瘤患者中单次/多次给药的安全性和耐受性；次要目的：评价注射用ATAP-M8在晚期实体瘤患者中单次/多次给药的药代动力学特征和免疫原性特征；评价注射用ATAP-M8治疗晚期实体瘤的初步疗效；探索注射用ATAP-M8治疗晚期实体瘤的Ⅱ期研究推荐剂量（RP2D）。

[Translation]

Primary purpose: To evaluate the safety and tolerability of single/multiple administration of ATAP-M8 for injection in patients with advanced solid tumors; Secondary purpose: To evaluate the pharmacokinetic characteristics and immunogenicity characteristics of single/multiple administration of ATAP-M8 for injection in patients with advanced solid tumors; To evaluate the preliminary efficacy of ATAP-M8 for injection in the treatment of advanced solid tumors; To explore the recommended dose (RP2D) of Phase II study of ATAP-M8 for injection in the treatment of advanced solid tumors.

Start Date17 Feb 2025

Sponsor / Collaborator

Beijing Aitaipu Biomedical Technology Co., Ltd

100 Clinical Results associated with ATAP-M8

Login to view more data

100 Translational Medicine associated with ATAP-M8

Login to view more data

100 Patents (Medical) associated with ATAP-M8

Login to view more data

100 Deals associated with ATAP-M8

Login to view more data